The Portuguese Health Authority (Infarmed) has approved Sandoz’s AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to developer Vectura. Sandoz licensed AirFluSal Forspiro from Vectura in 2006.
The Portuguese approval covers the 50-250 and 50-500 µg dosage forms. AirFluSal Forspiro is now approved in ten European countries, South Korea, and Mexico.
Sandoz Head of Global Respiratory Jan-Torsten Tews commented, “We look forward to launching Airflusal Forspiro in Portugal in the near future and making this important respiratory product available to those suffering from asthma and COPD. This is an affordable and award winning new therapeutic option, developed in close collaboration with patients.”
Read the Sandoz press release.
Read the Vectura press release.
